[PDF][PDF] Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole …
IE Smith, M Dowsett, SR Ebbs, JM Dixon… - Journal of clinical …, 2005 - researchgate.net
IE Smith, M Dowsett, SR Ebbs, JM Dixon, A Skene, JU Blohmer, SE Ashley, S Francis…
Journal of clinical oncology, 2005•researchgate.netPurpose The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen
(IMPACT) trial was designed to test the hypothesis that the clinical and/or biologic effects of
neoadjuvant tamoxifen compared with anastrozole and with the combination of tamoxifen
and anastrozole before surgery in postmenopausal women with estrogen receptor (ER)–
positive, invasive, nonmetastatic breast cancer might predict for outcome in the Arimidex,
Tamoxifen Alone or in Combination (ATAC) adjuvant therapy trial.
(IMPACT) trial was designed to test the hypothesis that the clinical and/or biologic effects of
neoadjuvant tamoxifen compared with anastrozole and with the combination of tamoxifen
and anastrozole before surgery in postmenopausal women with estrogen receptor (ER)–
positive, invasive, nonmetastatic breast cancer might predict for outcome in the Arimidex,
Tamoxifen Alone or in Combination (ATAC) adjuvant therapy trial.
Purpose
The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) trial was designed to test the hypothesis that the clinical and/or biologic effects of neoadjuvant tamoxifen compared with anastrozole and with the combination of tamoxifen and anastrozole before surgery in postmenopausal women with estrogen receptor (ER)–positive, invasive, nonmetastatic breast cancer might predict for outcome in the Arimidex, Tamoxifen Alone or in Combination (ATAC) adjuvant therapy trial.
researchgate.net